Keng-liang P. Wu
Kaohsiung, KHQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Alternation of the oral, gastric and stool microbiome in patients with reflux esophagitis and Barrett's esophagus.
Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Published: March 16, 2025
Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Journal: Inflammatory bowel diseases
Published: September 20, 2022
Autonomic impairment in treatment-naive patients with chronic hepatitis B and C infections.
Journal: Autonomic neuroscience : basic & clinical
Published: June 11, 2021
The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: February 11, 2021
Extremity risk factors of sepsis for gastrointestinal endoscopy in patients with liver cirrhosis.
Journal: BMC gastroenterology
Published: February 06, 2021
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice.
Journal: Infection and drug resistance
Published: January 31, 2021
The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Journal: Biomedical journal
Published: August 25, 2020
Risks of adverse events for users of proton-pump inhibitors plus aspirin or clopidogrel in patients with aspirin-related ulcer bleeding.
Journal: Journal of gastroenterology and hepatology
Published: June 30, 2020
A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial.
Journal: Infection and drug resistance
Published: May 08, 2019
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication.
Journal: Infection and drug resistance
Published: November 23, 2018
First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus.
Journal: Infection and drug resistance
Published: November 14, 2018
Last Updated: 09/26/2026